| PESUA17 | Role of UHRF1 in HIV-1 transcriptional regulation | Poster exhibition | Host cellular factors and viral mechanisms of HIV/SIV persistence and latency |
| EPF042 | Routine domestic abuse (DA) enquiring in people living with HIV (PLWH) | E-poster | Sexual- and/or gender-based inequalities, inequities and violence |
| EPA058 | Rufinamide-induced autophagy cell death in HIV-1-infected macrophages | E-poster | Strategies to reduce/eliminate viral reservoirs |
| EPC339 | Safe index testing as a high yielding HIV case identification strategy, the successful implementation by Oljabet Health Center, Laikipia, Kenya | E-poster | Facility-based HIV testing strategies |
| EPLBB05 | Safety and effectiveness outcomes from the Carisel study: phase 3b hybrid-3 implementation study integrating cabotegravir + rilpivirine long-acting into European clinical settings | E-poster | Long-acting agents and other drug delivery systems (e.g., injectables, implants, dual therapies, microneedle patches) |
| EPB159 | Safety and efficacy of switching to BIC/FTC/TAF plus DOR in HIV-infected patients with multiclass-resistant virus | E-poster | ART in highly treatment-experienced persons |
| EPC442 | Safety and immunogenicity of SARS-CoV-2 vaccines among a marginalized urban population of people living with HIV | E-poster | Epidemiology of COVID-19 among persons living with HIV and / or including tuberculosis |
| EPC471 | Safety and immunogenicity of Sputnik-V, AstraZeneca and Sinopharm vaccines against SARS-CoV-2 in people living with HIV | E-poster | COVID-19 prevention |
| EPB039 | Safety and pharmacokinetic of daily isoniazid/rifapentine (1HP) in adults with HIV on standard dose of dolutegravir | E-poster | Tuberculosis: Prevention, diagnosis, treatment |
| PEMOB28 | Safety outcomes among HIV-1 positive Zambian adults receiving Tenofovir Alafenamide combined with Dolutegravir: results from the VISEND clinical trial | Poster exhibition | Pregnancy (clinical management issues and pharmacokinetics) and contraception |